PLx Pharma Inc (PLXP) Receives Average Recommendation of “Hold” from Analysts

Shares of PLx Pharma Inc (NASDAQ:PLXP) have been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $13.00.

PLXP has been the topic of a number of recent analyst reports. ValuEngine upgraded shares of PLx Pharma from a “strong sell” rating to a “sell” rating in a report on Monday, December 4th. Zacks Investment Research downgraded shares of PLx Pharma from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Finally, Janney Montgomery Scott initiated coverage on shares of PLx Pharma in a report on Friday, January 19th. They set a “buy” rating and a $14.00 target price on the stock.

PLx Pharma (PLXP) opened at $6.25 on Tuesday. PLx Pharma has a fifty-two week low of $5.60 and a fifty-two week high of $12.80. The company has a debt-to-equity ratio of 0.56, a current ratio of 8.99 and a quick ratio of 8.88.

A hedge fund recently bought a new stake in PLx Pharma stock. Brown Advisory Inc. bought a new position in shares of PLx Pharma Inc (NASDAQ:PLXP) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 110,000 shares of the biotechnology company’s stock, valued at approximately $759,000. Brown Advisory Inc. owned about 1.26% of PLx Pharma at the end of the most recent quarter. 25.54% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Zolmax and is owned by of Zolmax. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://zolmax.com/investing/plx-pharma-inc-plxp-receives-average-recommendation-of-hold-from-analysts/1942968.html.

PLx Pharma Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Capital Fund Management S.A. Takes $455,000 Position in Kulicke and Soffa Industries Inc.
Capital Fund Management S.A. Takes $455,000 Position in Kulicke and Soffa Industries Inc.
Capital Fund Management S.A. Takes $482,000 Position in Nova Measuring Instruments Ltd.
Capital Fund Management S.A. Takes $482,000 Position in Nova Measuring Instruments Ltd.
Medpace  Given News Sentiment Rating of 0.19
Medpace Given News Sentiment Rating of 0.19
Pinebridge Investments L.P. Has $1.64 Million Position in Chart Industries, Inc.
Pinebridge Investments L.P. Has $1.64 Million Position in Chart Industries, Inc.
Capital Fund Management S.A. Buys 2,700 Shares of Tower International Inc
Capital Fund Management S.A. Buys 2,700 Shares of Tower International Inc
Pinebridge Investments L.P. Raises Stake in Delta Air Lines, Inc.
Pinebridge Investments L.P. Raises Stake in Delta Air Lines, Inc.


Leave a Reply

 
© 2006-2018 Zolmax.